Viatris completes $1.69 billion Pacira BioSciences acquisition
Viatris completed its acquisition of Pacira BioSciences after a tender offer for Pacira shares at $36.50 each in cash, a deal worth about $1.69 billion excluding fees and expenses.
Key takeaways
- Viatris (VTRS) completed its acquisition of Pacira BioSciences (PCRX) on Nov. 17, 2026, after a tender offer at $36.50 per share in cash. The deal is worth about $1.69 billion, excluding fees and expenses. Viatris expects Pacira to add $90 million to $100 million in revenue through Dec. 31, 2026.

Viatris (VTRS) completed its acquisition of Pacira BioSciences (PCRX) through a tender offer at $36.50 per share in cash.
The companies signed the merger agreement on Oct. 8, 2026. The total paid in the offer and the merger is about $1.69 billion, excluding related fees and expenses.
Peach Purchaser Sub Inc., a wholly owned Viatris subsidiary, began the tender offer on Oct. 30. It expired at 11:59 p.m. Eastern Time on Nov. 16, with 32,929,780 Pacira shares tendered, 66.46% of shares outstanding at expiration.
The shares were accepted for payment on Nov. 17, and the remaining conditions were satisfied or waived that day.
Peach Purchaser Sub merged into Pacira, which continues as a wholly owned Viatris subsidiary, without a Pacira stockholder vote. Pacira shares will be delisted from the Nasdaq Global Select Market.
Viatris will fund the purchase with cash on hand and short-term borrowings.
Viatris expects the deal to contribute total revenues of $90 million to $100 million from Nov. 17 through Dec. 31, 2026.